News | January 03, 2007

Poverty, Race Play Crippling Peripheral Vascular Disease Role

Non-white, low-income patients without commercial insurance are more likely to delay diagnosis of peripheral vascular disease (PVD), which often results in amputation of the lower limb(s) according to a study published in the January 2007 issue of the Journal of Vascular Surgery. In addition to the immense psychological tool of limb loss, financial impact of the care of the amputees is estimated to be more than $4 billion annually.

Independent of other variables and comorbidities, non-white patients, income levels (from low income zip codes where average annual income was less than $25,000), Medicaid and Medicare patients, and non-teaching hospitals adversely affected the amputations rates. Low-income, minority/non-white and those with Medicaid also presented more commonly with gangrene, according t o a release from the Society for Vascular Surgery.

Between 1998-2002 the clinical data of 240,740 patients with lower extremity ischemia (LER) who had revascularization was 66.3 percent and 122,453 who had major amputation (AMP) was 33.7 percent. Patient composition included 55 percent men and 45 percent women. Data was collected from the Nationwide Inpatient Sample, which offers discharge data on 20 percent of all U.S. patients from non-federal hospitals.

“Independent of other variables we found that patients 72 years and older, diabetics and those with renal failure more commonly had amputation,” said Mohammad Hamed Eslami, MD, assistant professor of surgery in the division of vascular surgery at the University of Massachusetts Medical School in Worcester.
“Compared to the general population, male and female composition was skewed significantly in the amputation and bypass groups,” said Dr. Eslami. “The bypass group had a higher ratio of males (57 percent male versus 43 percent female), whereas the amputation group had a comparatively higher female ratio (51 percent male versus 49 percent female). Independently, the female gender led to higher risk of amputation than male patients.”

The LER group had 80 percent white patients, while the AMP group had 61.2 percent, when compared with the general population of 74.1 percent. Conversely, non-white patients were more prominently represented in the AMP groups (38.8 versus 25.9 percent).

Diabetes and chronic renal failure were more common among the AMP group while chronic obstructive pulmonary disease, hypertension and coronary artery disease were more frequent in the LER group.

Compared with private/HMO patients, both Medicaid (1.9 fold) and Medicare (1.8 fold) patients were more likely to have amputations. The study noted that Medicaid patients often seek help in the emergency department rather than early and regular care. It also was noted that diabetes, an independent predictor of amputation, was more common among nonwhites (53.1 versus 37.1 percent), and that the diabetes rate decreases as income increases.

Dr. Eslami added that age and diabetes may partially explain the higher rate of amputation among Medicare recipients, higher amputation rates among relatively younger Medicaid recipients and presentation of gangrene among these patients.

“This study gives a very clear snapshot of the disparities of care and higher amputation rates among minorities and poor patients,” said Dr. Eslami. “This socioeconomic group, which has a comparatively higher rate of diabetes and renal failure, must be educated about peripheral artery disease. Studies such this indicate the need for an educational campaign regarding the signs and symptoms of PVD and priority screening for the underserved, to decrease amputation rates. Also, there needs to be a focus on the removal of barriers to accessible, appropriate medical care for this sector of the population.”

For more information visit www.jvascsurg.org. or www.VascularWeb.org.

Related Content

Intact Vascular Inc. received U.S. Food and Drug Administration (FDA) market clearance for the Tack Endovascular System. This is a purpose-built dissection repair device implanted post-angioplasty in patients with peripheral arterial disease (PAD).
Technology | Peripheral Artery Disease (PAD) | April 15, 2019
April 15, 2019 – Intact Vascular Inc. received U.S.
The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

The Boston Scientific Eluvia self-expanding, drug-eluting peripheral stent. It outperformed the Cook Zilver stent in the IMPERIAL Trial presented at TCT 2018.

Feature | Peripheral Artery Disease (PAD) | January 30, 2019 | Dave Fornell, Editor
In recent years, there has been a lot of focus by vendors on developing better stenting technologies to treat...
The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

The safety of paclitaxel-eluting stents and drug-coated balloons was called into question in a recent study that showed higher mortality rates after two years. The Cook Zilver PTX paclitaxel-eluting peripheral stent is among the devices included in that study.

Feature | Peripheral Artery Disease (PAD) | January 25, 2019 | Dave Fornell, Editor
The anti-proliferative drug paclitaxel has been used as a coating on coronary stents to prevent restenosis since 2003
Lumee Oxygen Platform Measures Treatment Response in Critical Limb Ischemia
News | Peripheral Artery Disease (PAD) | January 25, 2019
January 25, 2019 — Profusa announced promising...
BEST-CLI Trial Examining Critical Limb Ischemia Treatment Options Nears Enrollment Goal
News | Peripheral Artery Disease (PAD) | January 23, 2019
A new report in the Journal of Vascular Surgery chronicles a multi-site randomized controlled trial comparing treatment...
FDA Issues Letter About Paclitaxel Coated Balloons and Eluting Stents
News | Peripheral Artery Disease (PAD) | January 17, 2019
The U.S. Food and Drug Administration (FDA) issued a letter Jan. 17, 2019, to healthcare providers regarding a recent...
New Appropriate Use Criteria Released for Peripheral Artery Interventions
News | Peripheral Artery Disease (PAD) | December 19, 2018
A new set of appropriate use criteria (AUC) released Dec. 17 by a group of cardiovascular professional societies...
Lithotripsy Safe and Effective in Calcified Stenotic Peripheral Arteries
News | Peripheral Artery Disease (PAD) | December 04, 2018
New results from the DISRUPT PAD II study showed no perforations, embolization, reflow or abrupt closures with the...
Lutonix 014 Drug-Coated Balloon Safe and Effective Below the Knee
News | Peripheral Artery Disease (PAD) | November 07, 2018
The Lutonix Drug-Coated Balloon (DCB) showed statistically significant safety equivalence with a standard percutaneous...
Overlay Init